New generation vaccines take advantage of NGS

The genome era fostered by Next Generation Sequencing has started a new revolution in vaccine development.

Thanks to the massive sequencing technologies we know the sequences of multiple isolates of the most important pathogens. It allows us to select, for example, the set of membrane proteins or the secreted proteins of the different isolates of a pathogen. Thus, genomic information has been successfully used for the identification of novel protein antigens to develop vaccines against various human pathogens.

The concept of reverse vaccinology was applied for the first time to serogroup B of Neisseria meningitidis (MenB).

The availability of genome sequences for the different isolates of a single species enables quantitative analyses of their genomic diversity through comparative genomic analyses.

We offer a complete service for the design and the use of Next Generation Sequencing in vaccine development projects.

 

Contact us by e-mail:

  • info@era7.com

 

Or using this form

PRIVACY POLICY: In compliance with the requirements of the current legislation on protection of personal data, Era7 Information Technologies SL informs you that the data collected through this form will be treated with the purpose of sending information about our products, services and activities. We also inform you that the data collected will not be communicated to third parties unless there is a legal obligation and that, in the case of authorizing the receipt of information by email, your data may be transferred to servers located in the United States whose owner company (The Rocket Science Group LLC - Mailchimp) is under the agreement of Privacyshield. You can exercise the rights of access, rectification, cancellation or opposition through the e-mail address info@era7bioinformatics.com, as well as through the means detailed in the additional information on our Privacy Policy.


Please write de text that appears in the image
* Required fields.